

SUPPORTING INFORMATION:

Towards the Optimization of Dinitrosyl Iron Complexes as Therapeutics for Smooth Muscle Cells

Chase Pectol¹, Sarosh Khan^{1,4}, Rachel B. Chupik¹, Mahmoud Elsabahy^{1,4}, Karen L. Wooley^{1,2,3,4}, Marcetta Y. Darensbourg^{1*}, and Soon-Mi Lim^{1,4*}

¹Departments of Chemistry, ²Chemical Engineering, ³Materials Science & Engineering, and ⁴the Laboratory for Synthetic-Biologic Interactions, Texas A&M University, College Station, Texas 77842-3012, United States

Contents:

S1 – Other trials of MTS viability assay curves of SMC treated with reported DNIC complexes	2
S2 – MTS assay results for RAW 264.7 cells treated with DNIC's and DEANO	3
S3 – The expression of the mouse cytokines, regulated upon activation normal T-cell expressed and presumably secreted (RANTES) (left panel) and tumor necrosis factor- α (TNF- α) (right panel), following the treatment of RAW 264.7 cells with media (control), DEANO, neoDNIC, SGluNHC, SGluRRE, SPhNHC and SPhRRE at 5 μ M for 24 h.	4
S4 – Confocal microscopy images of intracellular NO content upon treatment with neoDNIC	5
S5 – Confocal microscopy images of intracellular NO content upon treatment with SPh/SGluRRE and SPh/SGluNHC	6




Figure S1. MTS viability assay curves for SMC grown to confluence treated with DNIC's at varying concentrations. Each trial is a set of biological triplicates.




Figure S2. MTS viability assay curves for RAW 264.7 cells grown to confluence treated with DNIC's at varying concentrations. Each trial is a set of biological triplicates.




Figure S3: The expression of the mouse cytokines, regulated upon activation normal T-cell expressed and presumably secreted (RANTES) (left panel) and tumor necrosis factor- α (TNF- α) (right panel), following the treatment of RAW 264.7 cells with media (control), **DEANo**, **neoDNIC**, **SGluNHC**, **SGluRRE**, **SPHNHC** and **SPHRRE** at 5 μ M for 24 h.




Figure S4: Confocal microscopy images collected with a 10x objective (image size $1.3\ \mu\text{m} \times 1.3\ \mu\text{m}$). The brighter the green fluorescence, the more nitric oxide present. Concentrations of DNIC are as follows. $30\ \mu\text{M}$: **SPhRRE**, **SGLuRRE**; $5\ \mu\text{M}$ **neoDNIC**; $3\ \mu\text{M}$: **SPhNHC**, **SGLuNHC**. To aid in visualization, $100\ \mu\text{M}$ L-NNA (L-nitroarginine), an NOS inhibitor was added to each well.




Figure S5: Confocal microscopy images collected with a 10x objective (image size $1.3\ \mu\text{m} \times 1.3\ \mu\text{m}$). The brighter the green fluorescence, the more nitric oxide present. Concentrations of DNIC are as follows. $30\ \mu\text{M}$: **SPhRRE**, **SGLuRRE**; $3\ \mu\text{M}$: **SPhNHC**, **SGLuNHC**. To aid in visualization, $100\ \mu\text{M}$ L-NNA (L-nitroarginine), an NOS inhibitor, was added to each well. No treatment indicates that only L-NNA was present and no DNIC treatments were added.